S7771
(S)-(−)-スルピリド
≥98% (titration)
別名:
(S)-5-アミノスルホニル-N-[(1-エチル-2-ピロリジニル)メチル]-2-メトキシベンズアミド, レボスルピリド
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C15H23N3O4S
CAS番号:
分子量:
341.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (titration)
Quality level:
Quality Level
assay
≥98% (titration)
mp
183-186 °C (lit.)
originator
Sanofi Aventis
storage temp.
2-8°C
SMILES string
CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O
InChI
1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
InChI key
BGRJTUBHPOOWDU-NSHDSACASA-N
Gene Information
human ... DRD2(1813), DRD3(1814)
rat ... Adra1a(29412), Drd2(24318), Drd3(29238), Htr1a(24473), Htr2a(29595)
類似した製品をお探しですか？ 訪問 製品比較ガイド
Application
(S)-(−)-Sulpiride was used to study the effect of dopamine D2 receptor function on activation of KCNQ potassium channels10 and on depression-like behavior in ovariectomized female rats.11
Biochem/physiol Actions
D2ド-パミンレセプタ-アンタゴニストであり、抗精神病薬です。
(S)-(−)-Sulpiride or Levosulpiride blocks the inhibitory enteric D2 receptors (neuronal and muscular). It has prokinetic activity and is effective in the treatment of functional dyspepsia and gastroparesis in insulin-dependent diabetes mellitus patients.7,8 Since dopamine controls human sexual function, (S)-(−)-Sulpiride is reportedly effective in treatment of erectile dysfunctions.9
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
S7771-5G: + S7771-10G: + S7771-VAR: + S7771-BULK: + S7771-50G:
jan
P Melga et al.
Diabetes care, 20(1), 55-58 (1997-01-01)
We evaluated the effect of chronic administration of levosulpiride, a prokinetic drug that is a selective antagonist for D2 dopamine receptors, on the glycemic control of IDDM subjects. The study was performed on 40 long-standing IDDM subjects with clinical signs
Takuya Hikima et al.
Cell reports, 35(1), 108951-108951 (2021-04-08)
Somatodendritic dopamine (DA) release from midbrain DA neurons activates D2 autoreceptors on these cells to regulate their activity. However, the source of autoregulatory DA remains controversial. Here, we test the hypothesis that D2 autoreceptors on a given DA neuron in
Jong Sam Baik et al.
Movement disorders : official journal of the Movement Disorder Society, 23(5), 746-748 (2008-01-11)
We describe three patients who presented with 4 to 5 Hz tremors of the suprahyoid region of the neck. Two developed their tremors in association with levosulpiride treatment. When they opened their mouths, the neck tremors disappeared; no tongue tremors
C Mansi et al.
Alimentary pharmacology & therapeutics, 14(5), 561-569 (2000-05-03)
The efficacy of several prokinetic drugs on dyspeptic symptoms and on gastric emptying rates are well-established in patients with functional dyspepsia, but formal studies comparing different prokinetic drugs are lacking. To compare the effects of chronic oral administration of cisapride
M Tonini et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 35(4), 244-250 (2003-06-13)
The dopamine D2 receptor antagonist levosulpiride is a substituted benzamide derivative, whose gastrokinetic properties are exploited clinically for the management of functional dyspepsia. However, for other benzamide derivatives, such as cisapride and mosapride, agonism towards serotonin 5-HT4 receptors is considered
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）